Page 7 - CAR-T Brochure 2024
P. 7
Does my relapsed or refractory CLL need additional treatment?
YES
YES
NO
Is my relapsed or refractory CLL likely to respond to an approved therapy?
NO
CAR-T therapy is not needed at this time.
Discuss other approved and experimental treatments including CART-T with your healthcare provider.
Consider discussing CAR-T and other clinical trials with your healthcare provider.
How does someone with CLL know when CAR-T therapy might be a good treatment option for them?
CAR-T therapy might be the best treatment option when:
• The person with CLL is well enough to tolerate a
short duration of a potentially challenging therapy, AND
• Has a caregiver who can provide support during the
CAR-T process, AND
• The person with CLL desires a type of treatment that offers a possible deep and long response even though it is still considered experimental, OR
• Other treatment options are unlikely to work or provide a deep and long-lasting response.
CAR-T is a new and different, powerful cell-based therapy that may offer CLL patients great hope for deep and durable remissions.
Where can I go to find more information about CAR-T therapy for CLL?
Please visit CLLSociety.org/CAR-T
Brought to you by CLL Society with support from Bristol Myers Squibb and Novartis.
